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Increased Incidence of Hypothyroidism in 
Primary Biliary Cirrhosis 
GRACE H. ELTA, MD, ROBERT A. SEPERSKY, MD, MICHAEL J. GOLDBERG, MD, 
CHRISTINE M. CONNORS, KENNETH B. MILLER, MD, and MARSHALL M. KAPLAN, MD 
We examined the thyroid status of  58 patients with primary biliary cirrhosis (PBC) using 
total serum thyroxin, thyroid hormone binding ratio, free thyroxin index, serum TSH, 
antithyroglobulin, and antimicrosomal antibodies. Seven patients were known to be 
hypothyroid prior to the diagnosis of  PBC. Six additional patients were found to have 
biochemical evidence of  hypothyroidism. The prevalence of  hypothyroidism was 12% if we 
include only those six PBC patients with newly diagnosed hypothyroidism or 22% if we 
include all 13 patients. Five of  the 58 patients had evidence for an elevation of  thyroid 
hormone binding capacity. Three hypothyroid patients had normal total thyroxins with 
low thyroid hormone binding ratios. Two euthyroid patients had elevated total T4s with 
low thyroid hormone binding ratio and normal FTI. The prevalence of  positive antimicro- 
somal antibodies was 34%, including 11 euthyroid PBC patients. The prevalence of  
positive antithyroglobulin antibodies was 20% including five euthyroid patients. There 
was no association between HLA DR3 or DR5 and the patients with hypothyroidism and/ 
or antithyroid antibodies. Because fatigue, lethargy, and anorexia as well as hypercholes- 
terolemia are common features of  both hypothyroidism and PBC, patients with PBC 
should be screened for evidence of  thyroid dysfunction. Thyroid disease may precede the 
diagnosis o f  PBC by several years. Therefore, the development of  cholestatic liver disease 
in a patient with known autoimmune thyroiditis should arouse suspicion of  PBC. 
Primary biliary cirrhosis (PBC) is a progressive 
liver disease of unknown etiology for which only 
symptomatic treatment exists (1). As in most chron- 
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ic illnesses, detection and treatment of any associat- 
ed diseases are very important in the overall care of 
patients with PBC. Among the array of symptoms 
manifested by patients with this disease are fatigue, 
lethargy, and anorexia (2). These are nonspecific 
symptoms associated with a large number of dis- 
eases. In patients with PBC these symptoms are 
usually attributed to the chronic liver disease. 
Patients with PBC have an increased incidence of 
several autoantibodies including antismooth muscle 
(4), antinuclear (4, 5), antimitochondrial (3-5), and 
antithyroglobulin (5) antibodies. In addition, auto- 
immune disorders such as Sjogren's syndrome, 
rheumatoid arthritis, CRST syndrome, and autoim- 
mune thyroiditis occur with increased frequency in 
patients with PBC (6). Hypothyroidism has been 
noted to occur in PBC (7). Recently, biochemical 
evidence of hypothyroidism was found in 18% of a 
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TABLE 1. PRIMARY BILIARY CIRRHOSIS PATIENTS WITH PRESUMPTIVE OR DEFINITE THYROID DISEASE* 
TSH Total T4 
PBC AMcA ATG (N1 < 8.0 (N1:4.2-12 THBR FTI 
Patient stage titer titer p,U/ml) p,g/lO0 ml) (N1:0.82-1.2) (N1.'5.5-11.5) 
Newly diagnosed hypothyro id ism 
KS III 1:400 1:100 90.5 0.2 0.60 1.2 
MG III 1:1600 1:6400 14:3 6.3 0.77 4.9 
BL  I1 1:6400 1:100 15:1 3.3 0.9 3.0 
JT II 1:25,600 1 : 100 22.4 6.0 0.8 4.8 
HB IV 1:1600 1:100 12.3 4.5 1.02 4.6 
SK I 1:102,400 neg 11.3 4.0 0.94 3.8 
Taking thyroid rep lacement  medicine 
MC IV neg neg 
MR III 1:1600 1:6400 
AM III neg neg 
ER III 1:25,600 neg 
MD IV 1:1600 1:400 
RK II neg neg 
RK IV neg neg 
Euthyroid AMcA and/or ATG positive 
MT II 1 :25 ,600 1:6400 2.5 9.6 0.9 9.6 
PW I 1 :25 ,600  1:400 7.4 7.9 0.99 7.8 
LM III 1:400 1:400 5.3 5.8 0.88 5.1 
JC 1 1 : 100 neg 2.5 8.3 1.09 9.1 
PM III 1:400 neg 5.9 8.0 0.88 6.8 
CM IV 1:400 neg 3.3 9.0 0.95 8.6 
JN III 1:100 neg 5.7 7.3 0.99 7.2 
JC III 1:6400 neg 2.4 12.5 0.98 12.3 
FE II 1:400 neg 2.5 6.5 1.04 6.8 
AL IV 1:400 neg 7.1 11.0 1.04 11.3 
AD IV neg 1:100 5.2 6.3 0.83 5.2 
YK I 1:1600 1:400 3.1 7.7 1.5 8.9 
*AMcA = antirnicrosomal antibody; ATG = antithyroglobulin antibody; TSH = thyroid st imulating hormone;  T H B R  = thyroid 
hormone binding ratio; FTE = free thyroxin index (total T4 • THBR); total T4 = total serum thyroxin; neg = negative. 
g r o u p  o f  95 p a t i e n t s  wi th  P B C  (8). T h e r e  have  been  
conf l ic t ing r e p o r t s  r ega rd ing  t h y r o i d  h o r m o n e  b ind-  
ing c a p a c i t y  in PBC (7, 8). To e x p l o r e  fu r the r  and  
conf i rm these  f indings,  we  s c r e e n e d  ou r  PBC pa-  
t ients  wi th  to ta l  s e r u m  t h y r o x i n  (T4), t h y r o i d  hor-  
mone  b ind ing  ra t io  ( T H B R ) ,  f ree  t h y r o x i n  index  
(FTI ) ,  t h y r o i d  s t imula t ing  h o r m o n e  (TSH) ,  an t i thy-  
rog lobu l in  a n t i b o d y  ( A T A ) ,  and  a n t i m i c r o s o m a l  
a n t i b o d y  ( A M c A ) .  
MATERIALS AND METHODS 
All patients followed at New England Medical Center 
between January 1978 and June 30, 1982, with well 
characterized primary biliary cirrhosis were included in 
this study. All had liver biopsies consistent with PBC and 
common bile duct patency demonstrated by either intra- 
venous cholangiography, endoscopic retrograde cholan- 
giography, or laparotomy. Histologic staging of the dis- 
ease was done by currently accepted criteria (9). The 
group consisted of 53 females and five males. Antimito- 
chondrial antibody was positive in 53 patients (91%). 
Seven of the 58 patients were known to be hypothyroid 
prior to the diagnosis of their liver disease. All seven were 
taking thyroid hormone replacement.  
Total serum thyroxin (T4) was measured by a standard 
radioimmunoassay. Normal ranges are listed in Table 1 
and are _+ 2 sD of a previously obtained normal distribu- 
tion. Thyroid hormone binding ratio was measured as a 
triiodothyronine uptake (T3U) procedure which uses talc 
absorption of free [125I]T3 after adding the serum sample 
to a known amount of [IzSI]T3. The remaining [125I]T3 is 
then quantified. The thyroid binding ratio is expressed as 
a ratio of counts of [125I]T 3 of pooled normal serum to the 
counts of [~25I]T3 of patient serum. A pool of euthyroid 
sera is collected over several weeks by freezing the 
individual sera and then collectively mixing and refreez- 
ing the pool in small aliquots of  0.5 ml. The free thyroxin 
index is determined by multiplying the thyroid hormone 
binding ratio times the total serum thyroxin. Antithyro- 
globulin antibody and antimicrosomal antibody were 
measured by hemagglutination using the Sera-Tek anti- 
body kits (Ames, Elkhart,  Indiana). Thyroid stimulating 
hormone (TSH) was measured with a human TSH RIA kit 
(Abbott Laboratories,  North Chicago, Illinois). 
HLA-DR typing was done as follows: B and T lympho- 
cytes were isolated from peripheral blood using a nylon-  
wool column technique from a Ficol l -Hypaque prepared 
total lymphocyte fraction (10). Lymphocyte  assays with 
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peripheral T cell lymphocytes were performed using the 
standard NIH technique (l 1). Lymphocyte assays with 
peripheral B cells were performed according to the stan- 
dard NIH technique with increased incubation times of 1 
hr with sera and cells and 2 hr with complement at room 
temperature. The 58 PBC patients were compared with 63 
members of a local control panel and with 3811 individ- 
uals studied in the 8th International Workshop (12). 
RESULTS 
None of our PBC patients had a palpable goiter at 
the time of this study, although one patient had had 
a goiter surgically resected years before her PBC 
was diagnosed. Seven of our 58 patients were 
known to be hypothyroid prior to the diagnosis of 
their liver disease. In all, the diagnosis was based 
on low serum levels of T4. More complete testing of 
thyroid function was not done. These patients were 
all taking thyroid hormone replacement. Thyroid 
function tests and serum TSH determinations re- 
vealed an additional six patients with biochemical 
hypothyroidism. One of these six patients had pro- 
found depression of her serum thyroxin and had a 
free thyroxin index of 1.2. The incidence of hypo- 
thyroidism in our PBC population was 22% if we 
include all 13 patients in the analysis. If we include 
only the six whose hypothyroidism was diagnosed 
after the onset of the PBC but whose diagnosis of 
thyroid dysfunction was more securely established, 
the incidence is 12%. In either instance the inci- 
dence of hypothyroidism is much larger than the 
1.4-1.9% expected in a comparable group of wom- 
en (13) or the 5.9% found in a group of healthy men 
and women older than 60 years (14). 
Of the 13 patients with hypothyroidism, 10 had 
positive antimicrosomal antibodies and seven had 
positive antithyroglobulin antibodies. One of the 
patients taking thyroid replacement therapy who 
was negative for antithyroglobulin and antimicroso- 
mal antibodies had previously had a subtotal thy- 
roidectomy for goiter with pathologic examination 
revealing autoimmune thyroiditis. In addition to the 
patients found to be hypothyroid, 11 patients were 
found to have positive antimicrosomal and five 
positive antithyroglobulin antibodies. Two of these 
had low FTIs, 5.1 and 5.2, respectively, suggesting 
borderline hypothyroidism. Three of the six newly 
diagnosed hypothyroid patients had total T4s in the 
normal range. All, however, had low free thyroxin 
indexes. Two of the 45 euthyroid patients had 
elevated total serum T4s with low thyroid hormone 
binding ratios and normal FTI and free serum 
thyroxins. Table 1 presents the clinical data, PBC 
histologic stage, and autoantibody status of the 
hypothyroid patients and the patients with positive 
autoantibodies. There was no correlation in our 58 
patients between PBC stage and presence of hypo- 
thyroidism. There was no evidence for increased 
frequency of DR3 and DR5 in either the entire PBC 
group or in those with hypothyroidism and/or anti- 
thyroid antibodies when compared to the local or 
the international control gorups. Likewise there 
was no clustering of the hypothyroid PBC patients 
into any other HLA locus. An association between 
autoimmune thyroiditis and HLA-DR3 and DR5 has 
been previously noted (15, 16). 
Because hypercholesterolemia is a feature of 
both thyroprivic hypothyroidism and PBC, we fol- 
lowed the serum cholesterol levels in three of the 
four newly diagnosed hypothyroid patients as they 
were placed on thyroid hormone replacement to see 
if the levels would decrease from pretreatment 
values. Two had stage III disease and one had stage 
II. As depicted in Figure 1, serum cholesterol 
values were observed to decrease in all three pa- 
tients following the institution of thyroid hormone 
replacement. All three noted symptomatic improve- 
ment, primarily a lessening of fatigue. However, 
one patient also had a sustained improvement in 
liver function tests during the ensuing year with 
bilirubin falling from 8.2 to 3.5 mg/dl, alkaline 
phosphatase from 1598 to 878 IU, aspartate amino- 
transferase from 218 to 150 and cholesterol from 690 
mg/dl to 215. 
DISCUSSION 
Our data indicate that hypothyroidism is a fre- 
quent finding in PBC. Its onset may precede or 
follow that of PBC. The diagnosis of hypothyroid- 
ism preceded the diagnosis of PBC by an interval 
ranging from 18 months to 9 years in seven patients 
and followed the diagnosis of PBC in six patients by 
1-8 years. The incidence of hypothyroidism was 
22%, similar to the 18% incidence reported by 
Crowe et al (8). The six patients in whom hypothy- 
roidism was newly detected each had prominent 
symptoms of fatigue, lethargy, and anorexia which 
had previously been ascribed to their liver disease. 
Upon treatment for their thyroid disease, these 
symptoms improved. We believe that these nonspe- 
cific symptoms were at least partially due to the 
underlying hypothyroidism. In addition, elevated 
serum cholesterol levels, also believed to be due to 
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Fig 1. Response of serum cholesterol to thyroid replacement 
therapy in three patients with hypothyroidism and primary 
biliary cirrhosis. 
PBC, decreased in the three hypothyroid patients in 
whom it was serially measured after the patients 
were started on thyroid replacement therapy. The 
distinct decrease in the degree of hypercholesterol- 
emia which followed the institution of thyroid re- 
placement therapy suggests that the hypothyroid 
state was at least partially responsible for the ele- 
vated serum cholesterol. It is unlikely that the 
decrease in serum cholesterol was due to an inde- 
pendent effect of thyroxin therapy since thyroxin 
must be given in pharmacologic doses to normal 
subjects to lower serum cholesterol (17). 
We found a 34% prevalence of positive antimicro- 
somal antibodies and a 20% prevalence of antithy- 
roglobulin antibodies, similar to the incidence re- 
ported in previous studies (5, 8). Not unexpectedly, 
nine of 13 of the hypothyroid patients in our series 
had positive antimicrosomal antibodies, and eight 
had positive antithyroglobulin antibodies. One of 
the patients who was negative for both antibodies 
had a goitrous gland removed 9 years prior to the 
diagnosis of PBC with pathologic examination con- 
sistent with autoimmune thyroiditis. It is known 
that autoimmune thyroiditis may occur without 
detectable serum thyroid autoantibodies (18). How- 
ever, it is also known that antithyroid antibodies fall 
and may become negative with thyroid replacement 
therapy. Hence, four of the seven patients with 
preexisting hypothyroidism and no antithyroid anti- 
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bodies may have had such antibodies at the time 
their thyroid disease was first diagnosed. 
Schussler et al reported finding increased thyroid 
hormone binding proteins in PBC and chronic ac- 
tive hepatitis (7). They noted that this increase 
might result in a failure to recognize hypothyroid- 
ism or cause an overdiagnosis of hyperthyroidism 
on the basis of serum thyroxin alone. In our series, 
three of our six newly diagnosed hypothyroid pa- 
tients had normal total T4 determinations accompa- 
nied by the low FTI. Not shown in Table 1, two 
euthyroid patients had elevated total T4s with de- 
creased thyroid hormone binding ratios. Therefore, 
five of our 58 patients (9%) had evidence suggestive 
of increased thyroid binding. This finding is in 
agreement with Schussler et al (7) and is different 
from Crowe et al (8) who found no evidence of 
increased thyroid hormone binding in PBC. 
Our results strongly support the concept that 
thyroid disease is frequently associated with PBC 
and may relate to an autoimmune process involving 
both the thyroid gland and the hepatic bile ducts. 
We detected 12 patients with positive antimicroso- 
real and/or antithyroglobulin antibodies who were 
euthyroid by standard tests. Two of these 12 had 
borderline low free thyroxin index determinations, 
but their serum TSH levels were not frankly elevat- 
ed. It will be of interest to follow these patients with 
periodic TSH levels since the proportion of patients 
with autoimmune thyroiditis that become biochemi- 
cally hypothyroid increases with time (19). Alterna- 
tively, TRH stimulation tests can be employed to 
detect marginal hypothyroidism by observing an 
exaggerated TSH response (20). 
The symptoms of hypothyroidism can overlap 
with those of PBC. Hypercholesterolemia is a fea- 
ture of both conditions. Clearly, all patients with 
PBC should be screened with standard thyroid 
function tests and have their antimicrosomal anti- 
body status determined. This antibody is more 
sensitive than the antithyroglobulin antibody in 
screening for autoimmune thyroiditis (21). Euthy- 
roid patients who have positive antithyroglobulin 
and antimicrosomal antibodies should be observed 
periodically for the onset of biochemical hypothy- 
roidism, evidenced by either a rising TSH level or 
an exaggerated response to TRH stimulation. Con- 
versely, since many of our patients had hypothy- 
roidism detected years before the diagnosis of PBC, 
the discovery of an elevated alkaline phosphatase 
or the development of pruritus or jaundice in a 
patient with previously diagnosed autoimmune thy- 
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roiditis or hypothyroidism should immediately sug- 
gest the possibility of PBC. Awareness of the 
association between these two diseases will allow 
earlier diagnosis. 
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